Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer

Trial Profile

Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Sacituzumab govitecan (Primary) ; Carboplatin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 13 Nov 2017 According to an Immunomedics media release, BLA submission planned in the first quarter of 2018 to the FDA for accelerated approval as third-line treatment for mTNBC.
    • 02 Nov 2017 According to an Immunomedics media release, updated results from this study will be presented at the 2017 San Antonio Breast Cancer Symposium.
    • 09 Feb 2017 According to an Immunomedics media release, updated results from the study were presented at the 2016 San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top